Portfolio Update

Number 2 Best Buy Southern Company (NYSE: SO), has been one of our favorite holdings since we launched Global Income Edge in August of 2014. However, the company is currently being investigated by the Securities and Exchange Commission for allegations of mismanagement and fraud in the construction of its Kemper,… Read More

UBS Group’s (NYSE: UBS) deleveraging efforts, first announced in 2012, have been successful. The company recently received an upgrade from S&P Global ratings recognizing its efforts to reduce debt and to move away from investment banking to wealth management. S&P upgraded it from a BBB+ to A- and said UBS… Read More

Healthcare stocks displayed new vigor in the last quarter as earnings for the sector improved. In fact, according to J.P. Morgan, the earnings growth rate for the healthcare sector stands at about 5% year-over-year, compared with a roughly 6% decline for overall corporate earnings. We’ve been heartened by the renewed… Read More

With unprecedented declines in the Standard & Poor’s 500-stock index at the start of the year and increasingly volatile markets, investors have piled into safe-haven investments such as electric, water and propane utilities. In fact, the S&P 500 Utilities index is outpacing the broad index by nearly 6% so far… Read More

Though the company beat Wall Street estimates in the fourth quarter, HCP’s (NYSE: HCP) stock has been pummeled. It lost more than 20% since its earnings announcement on weak 2016 management guidance on challenges that have been already widely reported. The stock clearly has been oversold on panic selling as… Read More

According to Standard & Poor’s, only three of 10 S&P sectors are expected to post positive earnings growth for the fourth quarter, with telecommunications (17.9%) consumer discretionary (7.5%) and healthcare (5.6%) once again leading. We take a look at earnings forecasts of our various holdings in these sectors.In telecommunications, Conservative… Read More

British multinational pharmaceutical company GlaxoSmithKline (NYSE: GSK) declared in its last quarterly earnings call that the company’s integration and restructuring programs are on track, and sales are benefiting from recent new product introductions and most products recently acquired.So much so, that the company says it will meet its guidance for 2015… Read More